Shanghai Fosun Pharmaceutical (Group) Co., Ltd. develops, manufactures, and sells pharmaceutical products in Mainland China and internationally. It operates in five segments: Pharmaceutical Manufacturing, Medical Devices and Medical Diagnosis, Healthcare Service, Pharmaceutical Distribution and Retail, Other Business segments. The company offers pharmaceutical products in the areas of tumor, immune modulation, metabolism, alimentary and central nervous system. It also provides medical devices and diagnostic products. In addition, the company offers health care and hospital management services. Further, it engages in retail and wholesale distribution of medicines. Shanghai Fosun Pharmaceutical (Group) Co., Ltd. was founded in 1994 and is based in Shanghai, China.
General Outlook
In simple terms, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. has 4516.936 M shares that people are buying and selling right now. When we look at how much money they make before expenses, they keep 0.475% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is 0.071%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of 0.049%. This tells us they're good at keeping money after all costs.
Return on Investments
The company's asset efficiency, represented by a robust 0.018% return, is a testament to Shanghai Fosun Pharmaceutical (Group) Co., Ltd.'s adeptness in optimizing resource deployment. Shanghai Fosun Pharmaceutical (Group) Co., Ltd.'s utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of 0.044%. Furthermore, the proficiency of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. in capital utilization is underscored by a remarkable 0.036% return on capital employed.
Stock Prices
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.'s stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $14.4, while its low point bottomed out at $14.04. This variance in figures offers investors a lucid insight into the roller-coaster ride that is Shanghai Fosun Pharmaceutical (Group) Co., Ltd.'s stock market.
Liquidity Ratios
Analyzing 2196.HK liquidity ratios reveals its financial health of the firm.
The current ratio of 100.71% gauges short-term asset coverage for liabilities.
The quick ratio (69.54%) assesses immediate liquidity, while the cash ratio (38.70%) indicates cash reserves.
cards.indicator
cards.value
Current Ratio
100.71%
Quick Ratio
69.54%
Cash Ratio
38.70%
Profitability Ratios
2196.HK profitability indicators offer a lens into its earnings landscape. A pretax profit margin of 7.12% underscores its earnings before tax deductions.
The effective tax rate stands at 11.43%, revealing its tax efficiency.
The net income per EBT, 69.32%, and the EBT per EBIT, 99.88%, provide insights into its earnings hierarchy.
Lastly, with an EBIT per revenue ratio of 7.13%, we grasp its operational profitability.
cards.indicator
cards.value
Pretax Profit Margin
7.12%
Effective Tax Rate
11.43%
Net Income per EBT
69.32%
EBT per EBIT
99.88%
EBIT per Revenue
7.13%
Operational Efficiency
Operational metrics shed light on its business agility. With an operating cycle of 1.01, it details the span from stock purchase to revenue.
The 1 days it takes to settle debts showcases its creditor relations.
cards.indicator
cards.value
Days of Sales Outstanding
70
Days of Inventory Outstanding
125
Operating Cycle
199.42
Days of Payables Outstanding
105
Cash Conversion Cycle
95
Receivables Turnover
4.87
Payables Turnover
3.49
Inventory Turnover
2.93
Fixed Asset Turnover
1.90
Asset Turnover
0.36
Cash Flow Ratios
Peering into the cash flow metrics reveals liquidity and operational efficiency. The operating cash flow per share, 1.30, and free cash flow per share, -0.54, depict cash generation on a per-share basis.
The cash per share value, 5.67, showcases liquidity position.
A payout ratio of 1.23 highlights the portion of earnings distributed as dividends.
Lastly, the operating cash flow sales ratio, 0.08, offers insight into cash flow relative to sales.
cards.indicator
cards.value
Operating Cash Flow per Share
1.30
Free Cash Flow per Share
-0.54
Cash per Share
5.67
Payout Ratio
1.23
Operating Cash Flow Sales Ratio
0.08
Free Cash Flow to Operating Cash Flow Ratio
-0.41
Cash Flow Coverage Ratio
0.10
Short Term Coverage Ratio
0.18
Capital Expenditure Coverage Ratio
0.71
Dividend Paid and Capex Coverage Ratio
0.47
Dividend Payout Ratio
0.06
Debt and Leverage Ratios
Diving into debt and leverage metrics unveils the company's financial structure. The debt ratio, at 30.69%, highlights its total liabilities relative to assets.
With a debt-equity ratio of 0.75, we discern the balance between debt and equity financing.
The long-term debt to capitalization, 24.69%, and total debt to capitalization, 42.96%, ratios shed light on its capital structure.
An interest coverage of 2.09 indicates its ability to manage interest expenses.
cards.indicator
cards.value
Debt Ratio
30.69%
Debt Equity Ratio
0.75
Long Term Debt to Capitalization
24.69%
Total Debt to Capitalization
42.96%
Interest Coverage
2.09
Cash Flow to Debt Ratio
0.10
Company Equity Multiplier
2.45
Per Share Data
Speaking about the per share data offers a perceptive view of financial distribution. The revenue per share, 15.44, provides a glimpse into top-line earnings distributed across each share.
Net income per share, 0.89, reflects the portion of profit attributed to each share.
The book value per share, 17.04, represents the net asset value distributed per share, while the tangible book value per share, 10.59, excludes intangible assets.
cards.indicator
cards.value
Revenue Per Share
15.44
Net Income Per Share
0.89
Book Value Per Share
17.04
Tangible Book Value Per Share
10.59
Shareholders Equity Per Share
17.04
Interest Debt Per Share
13.59
Capex Per Share
-1.99
Growth Ratios
Delving into growth metrics provides a snapshot of financial expansion. The revenue growth rate, -5.81%, indicates top-line expansion, while the gross profit growth, -4.70%, reveals profitability trends.
EBIT growth, -60.13%, and operating income growth, -60.13%, offer insights into operational profitability progression.
The net income growth, -36.04%, showcases bottom-line expansion, and the EPS growth, -37.76%, measures the growth in earnings per share.
cards.indicator
cards.value
Revenue Growth
-5.81%
Gross Profit Growth
-4.70%
EBIT Growth
-60.13%
Operating Income Growth
-60.13%
Net Income Growth
-36.04%
EPS Growth
-37.76%
EPS Diluted Growth
-37.76%
Weighted Average Shares Growth
2.77%
Weighted Average Shares Diluted Growth
2.77%
Dividends per Share Growth
0.62%
Operating Cash Flow Growth
-19.05%
Free Cash Flow Growth
-15.03%
10-Year Revenue Growth per Share
244.29%
5-Year Revenue Growth per Share
56.31%
3-Year Revenue Growth per Share
30.50%
10-Year Operating CF Growth per Share
180.57%
5-Year Operating CF Growth per Share
8.89%
3-Year Operating CF Growth per Share
26.43%
10-Year Net Income Growth per Share
-2.14%
5-Year Net Income Growth per Share
-17.09%
3-Year Net Income Growth per Share
-37.76%
10-Year Shareholders Equity Growth per Share
147.71%
5-Year Shareholders Equity Growth per Share
53.63%
3-Year Shareholders Equity Growth per Share
17.97%
10-Year Dividend per Share Growth per Share
153.72%
5-Year Dividend per Share Growth per Share
30.10%
3-Year Dividend per Share Growth per Share
27.84%
Receivables Growth
-7.69%
Inventory Growth
9.52%
Asset Growth
5.88%
Book Value per Share Growth
-0.29%
Debt Growth
16.07%
R&D Expense Growth
1.02%
SGA Expenses Growth
7.16%
Other Metrics
Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, 62,716,335,481.513, captures the company's total value, considering both debt and equity.
Income quality, 1.18, assesses the reliability of reported earnings.
The sales, general, and administrative to revenue ratio, 0.03, gauges operational efficiency, while the research and development to revenue, 10.50%, highlights investment in innovation.
The ratio of intangibles to total assets, 24.88%, indicates the value of non-physical assets, and capex to operating cash flow, -156.31%, measures reinvestment capability.
cards.indicator
cards.value
Enterprise Value
62,716,335,481.513
Income Quality
1.18
Sales General and Administrative to Revenue
0.03
Research and Development to Revenue
10.50%
Intangibles to Total Assets
24.88%
Capex to Operating Cash Flow
-156.31%
Capex to Revenue
-12.89%
Capex to Depreciation
-179.98%
Stock-Based Compensation to Revenue
0.09%
Graham Number
18.47
Return on Tangible Assets
2.80%
Graham Net Net
-11.20
Working Capital
34,985,411
Tangible Asset Value
28,386,136,914
Net Current Asset Value
-23,060,775,429
Invested Capital
1
Average Receivables
10,382,837,320.5
Average Payables
6,221,829,882
Average Inventory
7,210,100,080
Days Sales Outstanding
88
Days Payables Outstanding
104
Days of Inventory On Hand
127
ROIC
3.63%
ROE
0.05%
Valuation Ratios
Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, 0.72, and the price to book ratio, 0.72, reflect the market's valuation relative to the company's book value.
The price to sales ratio, 1.41, provides a perspective on valuation in relation to sales.
Ratios like price to free cash flows, -40.11, and price to operating cash flows, 9.64, gauge market valuation against cash flow metrics.
cards.indicator
cards.value
Price Book Value Ratio
0.72
Price to Book Ratio
0.72
Price to Sales Ratio
1.41
Price Cash Flow Ratio
9.64
Price Earnings to Growth Ratio
1.72
Enterprise Value Multiple
7.22
Price Fair Value
0.72
Price to Operating Cash Flow Ratio
9.64
Price to Free Cash Flows Ratio
-40.11
Price to Tangible Book Ratio
0.90
Enterprise Value to Sales
1.51
Enterprise Value Over EBITDA
7.51
EV to Operating Cash Flow
18.37
Earnings Yield
5.78%
Free Cash Flow Yield
-4.65%
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”